The classification of tumor and tissue by molecular profiling is an essential aspect to diagnosing, staging, and treating cancer. More than selecting actionable targeted therapies, understanding the underlying makeup of a tumor is an essential aspect in personalizing care for individual patients.
Pathologists are able to use immunohistochemistry to determine protein expression in a given tumor sample; utilize fluorescence in situ hybridization to detect gene translocations, fusions, or amplification on a chromosomal level; measure the level of mutation expression or residual disease through quantitative polymerase chain reactions; and apply the future of detection technology through nextgeneration sequencing.
In 2018, the use of molecular profiling in cancer is more essential to treatment than ever.
The International Congress of Oncology Pathology™ agenda will provide attendees various focus topics to bring a greater view of the oncology pathology curriculum.
This year’s meeting will include topics such as: